Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...

(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...

FDA leaders framed the approval as a step forward for a cancer that has seen few therapeutic breakthroughs, stressing that the pancreatic cancer community deserves better options. The agency also ...

Lung cancer can be treated with small molecules formulated as pills as well as biological medications that are injected or infused, both as standalone treatments or as part of drug combinations. A ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...